Search		GO	Type Size:				Print This Page
Important Safety Information Full Prescribing Information

This information is intended for US healthcare professionals

Patient Profiles

Hyponatremia affects many types of patients with a range of comorbidities. That’s why we’ve provided a selection of patient profiles below—they are designed to help you better understand when and how to use Vaprisol in your own patients.

Postoperative Hyponatremia
42-year-old female with no significant medical history is status post hysterectomy for treatment of uterine fibroids. Learn more.

Hyponatremia in the ICU
72-year-old male with past medical history significant for congestive heart failure (CHF) was admitted to the ICU for treatment of community-acquired pneumonia (CAP). Learn more.

Hypervolemic Hyponatremia Secondary to CHF
78-year-old female was admitted to the hospital with hypervolemic hyponatremia due to congestive heart failure. Learn more.

Acute, Severe, Symptomatic Hyponatremia
32-year-old male was brought to the ED by friends with generalized tonic-clonic seizures. Learn more.

Hyponatremia Secondary to Acute Decompensated Heart Failure (HF)
75-year-old woman with chronic ischemic cardiomyopathy was admitted to the hospital for acute decompensated HF of several days’ onset. Learn more.

Hyponatremia After Subarachnoid Hemorrhage
46-year-old woman was admitted to the neurocritical care unit with a subarachnoid hemorrhage. Learn more.

Hyponatremia in a Patient With Subdural Hematoma
81-year-old male was admitted to the hospital with subdural hematoma and a medical history of CHF. Learn more.

NEXT: Safety

Stay Informed

Click here

How Common Is Hyponatremia?

Learn more about the incidence and impact of hyponatremia.

Click Here

Vaprisol Provides Proven Efficacy

Learn more about how Vaprisol raises serum [Na⁺] in a prompt but controlled fashion.

Click Here

Indication

Vaprisol is indicated for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients
Vaprisol is not indicated for the treatment of congestive heart failure. It should only be used for the treatment of hyponatremia in patients with underlying heart failure when the expected benefit of raising serum sodium outweighs the increased risk of adverse events

Important Safety Information

Vaprisol is contraindicated in patients with hypovolemic hyponatremia. In addition, coadministration of Vaprisol with potent CYP3A4 inhibitors, such as ketoconazole, itraconazole, clarithromycin, ritonavir, and indinavir, is contraindicated
Serum sodium, volume, and neurological status must be monitored frequently because Vaprisol potentially can cause overly rapid correction of sodium leading to serious sequelae
The use of Vaprisol in patients with hepatic impairment (including ascites, cirrhosis, or portal hypertension) or renal impairment has not been systematically evaluated. Use caution when administering Vaprisol to these patients
The most common adverse reactions reported were infusion site reactions (incidence of 73% and 63% for 20 mg/day and 40 mg/day, respectively) which were also the most common type of adverse reaction leading to discontinuation of Vaprisol. Discontinuations from treatment due to infusion site reactions were more common among Vaprisol-treated patients (3%) than among placebo-treated patients (0%). Other common adverse reactions were headaches (8%, 10%), hypokalemia (22%, 10%), orthostatic hypotension (14%, 6%), and pyrexia (11%, 5%) for Vaprisol 20 mg/day and 40 mg/day, respectively